Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: USPTO - is it REALLY the main issue?

Yes I can see where my statements of fact on the Agora board are the reason PTSC is trading at 8 cents and still falling. You continue to blame everyone but those who are actually responsible through their incompetence, mismanagement, and arrogance. All the while over 95 percent of the market value of PTSC has dissappeared. No matter how you want to spin it, out of over $130M NET that PTSC received from MMP revenues, they have less than $25M of it left, and have stewarded the company to a state of chaos and uncertainty that hasn't existed for over 5 years. And my posts are "the real problem". My oh my!

Your retorts remind me of an umbrella salesman who pees on your leg and then tells you it's raining, lol.

As for the NET "revenue"...(mind you, net income was never mentioned) characterizations, perhaps you had trouble comprehending the arrangement of the MMP revenue disbursment. Let me clarify. PDS collects the GROSS licensing revenues from infringers. Expenses for the prosecution of the patents and the licensing efforts are then deducted from those GROSS revenues. The remaining NET revenues are then split 50/50 between PTSC & TPL and distributed to each of them respectively.

But as you said I knew that....and so did you, but as usual, obfuscation is what you provide instead.

As for unpredictable revenues, 3 members of the BOD have been there through all of this. They have stewarded the disposition of over $130M in MMP revenues, but as you point out, despite that windfall, and over 5 years of opportunity (ESPECIALLY RIPE OPPORTUNITY, considering the market we've been through), they have been unable to secure through M&A, or build on their own, a consistenly profitable and predictable revenue stream.

Of couse THAT DOESN'T HELP! You STATE the obvious, but can't seem to SEE the obvious. lol

Share
New Message
Please login to post a reply